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Abstract: Toluene dioxygenase-catalysed cis-
dihydroxylations of substituted aniline and phenol substrates, 
with a Pseudomonas putida UV4 mutant strain and an 
Escherichia coli pCL-4t recombinant strain, yielded identical 
arene cis-dihydrodiols, which were isolated as the preferred 
cyclohex-2-en-1-one cis-diol tautomers. These cis-diol 
metabolites were predicted by preliminary molecular docking 
studie, of anilines and phenols, at the active site of toluene 
dioxygenase Further biotransformations of cyclohex-2-en-1-
one cis-diol and hydroquinone metabolites, using 
Pseudomonas putida UV4 whole cells, were found to yield 4-
hydroxycyclohex-2-en-1-ones as a new type of phenol  
bioproduct. Multistep pathways, involving ene reductase and 
carbonyl reductase-catalysed reactions, were proposed to 
account for the production of 4-hydroxycyclohex-2-en-1-one 
metabolites. Evidence for the phenol hydrate tautomers of 4-
hydroxycyclohex-2-en-1-one metabolites was shown by 
formation of the corresponding trimethysilyl ether 
derivatives. 
Keywords: aniline biotransformations; cyclohex-2-en-1-
one cis-diols; 4-hydroxycyclohex-2-en-1-ones; phenol 
hydrates. 
Introduction 
Enzyme-catalysed formation of phenol metabolites, 
from aromatic substrates, can proceed directly [1a] or 
indirectly, via transient intermediates. Phenols have 
been obtained indirectly by: (a) monooxygenase- or 
peroxygenase-catalysed arene epoxidation and 
spontaneous isomerization of arene oxide-oxepine 
intermediates[1b-e] or (b) dioxygenase-catalysed cis-
dihydroxylation of arenes[2a-m] and dehydration of cis-
dihydrodiol intermediates.[3a,b] Since their discovery by 
Gibson et al in 1968,[2a] more than four hundred cis-
dihydrodiol metabolites of substituted monocyclic and 
polycyclic arenes have been isolated and identified 
using, mainly, Pseudomonas putida mutant and 
Echerichia coli recombinant strains, expressing ring-
hydroxylating dioxygenases.[2b-m] Synthetic 
applications of enantiopure substituted benzene cis-
dihydrodiols 2, obtained as toluene dioxygenase 
(TDO)-catalysed cis- dihydroxylation products, from 
monosubstituted benzene substrates 1, continue to be 
widely reported, despite their limited stability.[2b-m] 
Dehydration of most cis-dihydrodiols 2, to yield a 
mixture of meta- and ortho-phenols 3 and 4, can occur 
at ambient temperature. The rate of dehydration and 
ratio of phenol isomers depend on the type of 
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Scheme 1. Tandem TDO-catalysed cis-dihydroxylation of monosubstituted benzenes (1) and phenols (3, 4) to yield cis-
dihydrodiols (2, 5, 7) and cyclohex-2-en-1-one cis-diol keto-tautomers (6, 8). 
substituent and pH of solution (Scheme 1).[3a,b]  
`Since phenols are widely distributed in the 
environment, as natural products, arene metabolites 
and environmental pollutants, their biodegradation 
pathways have been extensively studied.[4a-g] Bacterial 
metabolism of phenols often results in a wider range 
of metabolites, compared with most non-phenolic 
aromatic substrates. Recent biotransformation results 
of TDO-catalysed oxidations of phenols, e.g. 3 and 4, 
using P. putida UV4, showed that, in addition to the 
expected, catechol and hydroquinone metabolites, the 
corresponding cyclohex-2-en-1-one cis-diols 6a-d, 8a 
and 8b were also isolated, as the preferred keto 
tautomers of the initially formed enolic cis-
dihydrodiols 5a-d, 7a and 7b. The dihydroxylation 
was regio- and stereo-selective and cyclohex-2-en-1-
one cis-diols 6a-d, 8a and 8b were often found to be 
the major isolated metabolites. More than twenty 
members of this new cis-diol family have now been 
isolated.[5a-e] 
The biodegradation pathways, for anilines, 
have also been studied, due to their presence in the 
environment, as a result of the partial combustion of 
tobacco and automotive fuels, the application of 
pesticides / herbicides and the production of 
pharmaceuticals, dyestuffs and textiles.[6a-j] Many 
aniline derivatives are known to be genotoxic and 
cytotoxic, severely inhibiting cell growth in soil 
bacteria and slowing their mineralization.[6a,g] 
Similar to the metabolism of electron-rich 
phenols,[5a-e] ring hydroxylating dioxygenase-
catalysed biotransformations of electron-rich anilines 
(using Pseudomonads and other bacterial species) 
have also been reported, to yield catechol and 
hydroquinone metabolites.[6a-j] Aniline-, biphenyl- 
diphenylamine- and toluene-dioxygenases, have been 
reported to catalyse the oxidation of aniline 
substrates.[6d, f-i] Although cis-diol metabolites were 
often postulated as intermediates leading to the 
formation of catechol, hydroquinone and phenol 
metabolites of anilines,[6c-j] to date none have been 
detected or isolated. Thus, TDO-catalysed cis-
dihydroxylation, at the 1,2- and 2,3-bonds of 4-
chloroaniline, was proposed (using P. putida T57) as a 
possible initial step in the formation of both catechol 
and phenol metabolites.[6i] Biotransformations using 
other substituted anilines and bacterial strains, were 
also found to yield catechol and hydroquinone 
metabolites.[6a,c] In silico molecular docking studies, on 
aniline substrates, were thus conducted to: (a) predict 
the most favourable structures of expected metabolites 
and (b) compare the substrate docking results with the 
experimental results of TDO-catalysed cis-
dihydroxylation of aniline substrates. 
Results and Discussion 
P. putida UV4 biotransformations of aniline and 
phenol substrates, to yield cyclohex-2-en-1-one cis-
diols and 4-hydroxycyclohex-2-en-1-ones 
(i) Molecular docking of meta-substituted aniline 
substrates 9a-d with TDO  
Recent molecular docking studies, of the meta 
substituted phenols 3a and 3b, at the active site of 
TDO,[5f] were based on a comparison with an X-ray 
crystal structure of TDO and docked toluene 
substrate.[5g] These studies of TDO, without dioxygen 
incorporation (3EN1M model), provided preferred 
orientations of phenol substrates 3a and 3b (Scheme 
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Scheme 2. TDO-catalysed cis-dihydroxylation of meta-anilines 9 to yield cis-diols 6, cis-triols 12 and catechols 13. 
1) required for production of the corresponding enol 
cis-dihydrodiols 5a (12% docking iterations) and 5b 
(66% docking iterations). Catechols 13a and 13b 
(Scheme 2) were also predicted (54% docking 
iterations from phenol 3a and 34% from 3b). 
 
Docking of phenols 3a and 3b, with dioxygen 
incorporated TDO (3EN1M-O2 model), led to the 
predicted formation of catechols (54% docking 
iterations from 3a, 34% from 3b), but not of cis-
dihydrodiols 5a and 5b. Further biotransformation (P. 
putida UV4) of catechols 13, by a catechol 
dioxygenase-catalysed ring-opening process and other 
enzyme-catalysed reactions, gave a range of 
carboxylic acid metabolites. The formation of 
catechols, as arene metabolites, was also reported to 
inhibit the TDO activity, therefore reducing cis-
dihydrodiol yields.[6k] 
The predicted, and isolated, cyclohex-2-en-1-
one tautomers, derived from phenols, e.g. 6a and 6b, 
were single enantiomers, having an (S) absolute 
configuration at C-5. The main attractive interactions, 
at the TDO active site, involved: (i) hydrogen bonding 
of the phenol OH group with the C=O group of Gln-
215 and the imidazole ring of His-311, (ii) van der 
Waals interactions of the hydrophobic Me group of the 
phenol with the proximate alkyl (Ala-223, Val-309, 
Leu-321, Ile-324) and aryl (Phe-366) groups. 
It was speculated that similar binding of 
phenols with His-311 and Gln-215, at the TDO active 
site, might also apply to aniline substrate 
interactions.[5f] An earlier in silico molecular binding 
model for diphenylamine 1 (R=NHPh, Scheme 1), at 
the active site of biphenyl dioxygenase (BPDO,) led to 
the prediction that cis-dihydroxylation would yield 
aniline cis-dihydrodiol intermediate 2 (R=NHPh).[6e] 
Although BPDO-catalysed cis-dihydroxylation of 
substituted aniline 1 (R=NHPh)[6d] did not result in the 
detection of cis-diol 2 (R=NHPh), it was postulated 
that formation of the major metabolite, phenol 4 (R= 
NHPh), had resulted from dehydration of this transient 
intermediate.[6f] 
The qualitative nature of docking results 
recorded may not quantitatively reflect the 
experimental results (using P. putida UV4 whole 
cells), due to further metabolism by the co-induced 
enzymes. Apart from this caveat, the 3EN1M and 
3EN1M-O2 models, employed for TDO docking 
studies[5f]  of phenol substrates 3, were found to be 
useful predictors of the preferred regiochemistry and 
stereochemistry of cis-diol metabolites. These models 
have now been applied to cis-dihydroxylation of 
aniline substrates 9a-d (Scheme 2). From analysis of 
the data collected, it was predicted that the NH-imines 
11a-d would be the preferred tautomers of the initially 
formed enamine cis-diols 10a-d. It was also assumed 
that: (i) this type of imine would readily hydrolyse, 
during the biotransformation, to yield the 
corresponding cyclohex-2-en-1-one cis-diols 6a-d and 
(ii) as observed,[5c] the formation of cis-triols 12, via 
carbonyl reductase (CRED)-catalysed reduction of the 
ketone group in cis-diols 6, would occur using P. 
putida UV4 whole cells. The 3EN1M and 3EN1M-O2 
model docking studies of anilines 9a-d with TDO were 
also expected to provide evidence of preferred 
substrate orientations, leading to the formation of 
catechols 13a-d, via alternative types of transient 
aniline cis-diol intermediates 14a-d, resulting from 
cis-dihydroxylation at the 1,2- (ipso-ortho-) bond, as 
was proposed.[6c, 6e-i] 
cis-Dihydroxylation, at the 4,5-bond and % 
formation of enamine cis-diols 10a-d, was predicted 
(Table 1), from TDO docking orientations (using  
3EN1M model), for meta substituted anilines 9a (Fig. 
1A, 47%), 9b (Fig. 1B, 90%), 9c (Fig. 1C, 80%) and 
9d (Fig. 1D, 100%). The substrate binding, according  
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Table 1. Predicted, using the 3EN1M model of TDO, initial metabolites 11a-d, catechols 13a-c and isolated cis-
diol 6a-d products of 3-substituted aniline substrates 9a-d. 
 Substrate Figure Predicted
a Productb %c ΔGd KDe 
9a 3-Methoxyaniline  1A 11a 6a 47 -5.08 190.24 
  
   13a  26 -5.00 216.49 
9b 3-Methylaniline 
 1B 11b 6b 90 -5.27 137.66 
   13b  4 -5.14 169.39 
9c 3-Trifluoromethylaniline  1C 11c 6c 80 -5.14 171.53 
  
   13c  20 -5.07 191.97 
9d 3-Iodoaniline  1D 11d 6d 100 -6.13 31.88 
 
a Predicted metabolite; b Detected product; c Orientation occurrence; d Binding energy (kJ/mol);e Dissociation constant (µM) 
Figure 1. Molecular docking of meta substituted anilines 9a-d (Figs 1A-1D) at the active site of TDO
  
to the in silico docking, was facilitated by two major 
interactions: (i) van-der- Waals interaction of Ala-223, 
Val-309, Leu-321, Ile-324, Phe-366 and Phe-372 
amino acid residues with the substituents (Me, OMe, 
CF3, I) and (ii) H-bonding of the NH2 group to Gln 
215, and sometimes to His-311, in a similar manner to 
the docking of phenols.[5f] 
Val309 
Ile324 
Phe366 
Leu321 
His311 
Gln215 Ala223 
Asp219 
Phe372 
Phe216 
1A 1B 
1C 1D 
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The docking experiments (3EN1M model) of 
anilines 9a-d also led to the prediction that catechols 
13a-c might also be formed, via a minor pathway (4-
26% docking orientations), by dihydroxylation at the 
1,2-position, to yield intermediate cis-diols 14a-c. 
Employing the 3EN1M-O2 model of TDO, catechols 
13a-d were predicted to be the major metabolites (91-
100% docking orientations), without evidence of 
orientations of anilines 9a-d, leading to the 
corresponding cis-diols 10a-d (Supporting 
Information Figs. S1-S4). These results (3EN1M-O2 
model) were similar to those found earlier for phenol 
substrates 3a and 3b, where catechols 13a and 13b 
were predicted to be the major metabolites (54 and 
100% docking orientations) without evidence for the 
formation of cis-diols 5a and 5b.[5f] 
Based on these predictive in silico docking 
(3EN1M model) studies of TDO (Table 1), 
experimental evidence was sought, for TDO-catalysed 
cis-dihydroxylation of meta-anilines 9a-d, by LC-
TOFMS analysis of the crude biotransformed culture 
medium. Aniline substrates 9a-d were added, to P. 
putida UV4 cultures, under conditions similar to those 
reported for the corresponding meta-phenols 3a-d.[5a-e] 
The cyclohex-2-en-1-one cis-diols 6a-d, previously 
reported[5a-e] as phenol metabolites (Scheme 1), were 
also detected as aniline metabolites (Scheme 2), in 
accord with the predictions from in silico studies. The 
documented high cytotoxicity of anilines[6a,e] required 
a ten-fold reduction of the substrate concentration 
(0.05 mg/mL), for total conversion. Phenols 3a-d and 
corresponding anilines 9a-d, applied in the same low 
concentrations, produced comparable yields of 
cyclohexenone cis-diols 6a-d, which were identified 
by comparison (LC/TOFMS and GC-MS) with 
authentic samples. A sample of cis-diol 6a (ca. 6 mg) 
was also isolated by PLC, from the partial 
biotransformation using a higher concentration of 
aniline 9a; its structure, absolute configuration (4S,5S) 
and enantiopurity (>98% ee) was found to be identical 
with the metabolite derived from phenol 3a. From this 
result, combined with the in silico docking studies 
(Figs. 1A-D), it was predicted that the (S)-absolute 
configuration at the C-5 position and ee value (>98%) 
of cis-diol metabolites 6b-d, derived from the 
corresponding aniline substrates 9b-d, would be 
identical to those obtained from phenols 3b-d. 
The first objective of the study was to provide 
experimental evidence for TDO-catalysed cis-diol 
formation from aniline substrates, but the presence of 
other metabolites extended our interest into exploring 
the complete metabolic profile of anilines with the P. 
putida biocatalyst. A CRED enzyme, present in P 
putida UV4, was previously found to catalyse the 
reduction of the ketone group of metabolite 3c, to yield 
(1R,2S,4R)-6-(trifluoromethyl)cyclohex-5-ene-1,2,4-
triol 12c as a major bioproduct.[5c] A similar result was 
obtained with aniline substrate 9c when metabolites 
cis-diol 6c and triol 12c were identified by LC-
TOFMS analysis.  
Catechols were identified as aniline 
metabolites[6a-i]  and molecular docking (3EN1M and 
3EN1M-O2 models) experiments of TDO also 
suggested their formation from anilines 9a-d (Table 
1). LC-TOFMS analysis did not show direct evidence 
of catechol metabolites 13a-d, but indirect evidence, 
for the formation of catechol metabolite 9a, was 
observed by the formation of a carboxylic acid 
metabolite, whose molecular weight was consistent 
with structure 15a, formed by catechol dioxygenase-
catalysed ring opening and reductase-catalysed 
reduction (Fig.2). Similar ring-opened metabolites 15 
(R = Me, CF3) were previously reported from the 
corresponding phenols (3b and 3c) and catechols (13b 
and 13c).[5c] GC-MS analysis of trimethylsilylated 
samples, prepared from freeze-dried aliquots collected 
during TDO-catalysed dihydroxylation of anilines 9a 
and 9c, showed the presence of disilylated cis-diol 6a 
and 6c and derived hydroquinones 16a and 16c 
respectively, but no catechols were detected. The 
difficulty encountered in the detection of catechol 
metabolites 13a-d was probably due to: (i) the activity 
of a catechol dioxygenase enzyme present in P. putida 
UV4 and (ii) the low yields of all metabolites resulting 
from the cytotoxicity of aniline substrates.   
   Biotransformations of anilines 9a-d, with 
the recombinant strain, E. coli pCL-4t (expressing 
TDO), and LC-TOFMS analysis of the biotransformed 
aqueous material, again showed the presence of
 
Figure 2. Structures of metabolites 15-18 and 25.
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cyclohexenone cis-diol metabolites 6a-d. The reduced 
tolerance of E. coli cells, to the toxic aniline substrates, 
gave lower yields, compared with those found using P. 
putida UV4 cells. However, the E. coli pCL-4t 
biotransformation studies did provide evidence that 
TDO, rather than other types of dioxygenase, was 
responsible for the formation of cis-diols 6a-d.  
The biotransformation and molecular docking 
results, recorded for aniline substrates 9a-d, were 
consistent with a metabolic pathway via TDO-
catalysed formation of enamine cis-dihydrodiols 10a-
d, tautomerisation to the preferred NH-imine cis-diols 
11a-d, and rapid hydrolysis to yield cyclohex-2-en-1-
one cis-diols 6a-d (Scheme 2). Thus, the family of 
cyclohex-2-en-1-one cis-diol metabolites is formed, 
from both substituted phenols and anilines, by TDO-
catalysed cis-dihydroxylation. The molecular docking 
results can also be used to rationalize the reported 
formation of catechol and hydroquinone metabolites 
of aniline substrates,[6a-j] via ring hydroxylating 
dioxygenase catalysis. 
(ii) Biotransformations of phenol substrates, to 
yield 4-hydroxycyclohex-2-en-1-ones 
Earlier larger scale biotransformations of meta- and 
ortho-phenols 3 and 4, showed a wide range of 
metabolite types, including cyclohexenone cis-diols 6 
and 8, cyclohexene cis-triols 12, catechols 13, α-
hydroxycarboxylic acids 15, hydroquinones 16, 
cyclohexanone cis-diol isomers 17cis and 17trans and 
1,2,4-trihydroxycyclohexanes 18[5a-e] (Scheme 1 and 
Fig. 2). Several minor metabolites of methoxyphenols 
3a and 4a, however, remained unidentified;[5e] their 
structures, absolute configurations and metabolic 
pathways for their formation are presented in this 
section.  
Recrystallization of the crude mixture of 
metabolites, obtained from an earlier 
biotransformation of 3-methoxyphenol 3a (96 g), with 
glucose as carbon source, yielded cis-diol 6a as the 
major component (38% isolated yield, Scheme 1).[5e] 
The mother liquors from this recrystallization 
contained a mixture of unidentified minor metabolites, 
which were examined further during this study. 
Column chromatography of the mixture yielded a new 
minor metabolite (1% isolated yield), which was 
structurally identified as 4-hydroxy-3-
methoxycyclohex-2-en-1-one 19a ([]D -31.9).  
A chemoenzymatic synthesis of metabolite 
19a, starting from 2-bromo-2-cyclohexen-1-one 20 
established (4S) as its absolute configuration (Scheme 
3). Step (i) employed a CRED-catalysed reduction of 
the ketone group of 2-bromo-2-cyclohexen-1-one 20, 
to give the enantiopure synthetic precursor 
cyclohexenol 21S ([]D -80.3, 88%).[5h]
 Further 
chemical steps involved, hydroxyl group protection (ii, 
21S 22S, 94%), allylic oxidation (iii, 22S 23S, 
29%), nucleophilic substitution (iv, 23S 24S, 69%) 
and deprotection (v, 24S 19aS, 62%, Scheme 3). 
This synthetic sample of compound 19aS (>98% ee) 
had a higher optical rotation ([]D -48.8), compared 
with the corresponding metabolite (19aS) derived from 
phenol 3a. The lower enantiopurity (65% ee) of the 
minor metabolite, 4-hydroxy-3-methoxycyclohex-2-
en-1-one 19aS, compared to the major metabolite, 
(4S,5S)-3-methoxycyclohex-2-ene-1-one 6a (>98% 
ee), was of mechanistic relevance, in the context of 
biosynthetic pathways from 3-methoxyphenol 3a 
(Scheme 4), that will be discussed in Section (iii). 
A previous biotransformation (glucose as 
carbon source) of 2-methoxyphenol 4a (96 g), 
followed by column chromatography, resulted in a 
separable mixture of isomeric cyclohexanone cis-
diols, (2S,3S,4S)-17acis (13% isolated yield) and 
(2R,3S,4S) 17atrans (1% isolated yield).[5e]  Metabolites 
17acis and 17atrans were formed via an ene reductase 
(ERED)-catalysed reduction of the initial bioproduct, 
cyclohex-2-en-1-one cis diol 8a (Scheme 1). Using 
LC-TOFMS and GC-MS analyses, the relative ratios 
of metabolites from guaiacol 4a were found to vary 
widely, during time course studies of the 
biotransformations, depending on the choice of carbon
 
 
Scheme 3. Chemoenzymatic synthesis of 4-hydroxy-3-methoxycyclohex-2-en-1-one 19aS from 2-bromo-2-cyclohexen-1-
one 20.
 7 
source (glucose or pyruvate) and TDO source (P. 
putida or E. coli). Other metabolites from phenol 4a 
were identified as cyclohex-2-en-1-one cis diol 8a, 
hydroquinone 16a, catechol 13a and its α-
hydroxycarboxylic acid derivative 15a.  
Column chromatography fractions, from the 
earlier study,[5e]  that appeared to be an inseparable 
mixture of two unidentified isomeric metabolites of 
phenol 4a were retained for further examination. 
During the current study, this mixture, was finally 
separated by careful multiple elution PLC. The minor 
isomer (2% isolated yield) was indistinguishable from 
4-hydroxy-3-methoxycyclohex-2-en-1-one 19aS 
derived from 3-methoxyphenol 3a. The structure and 
absolute configuration of the major isomer (18% 
isolated yield, [α]D -29), was identified as (4S)-4-
hydroxy-2-methoxycyclohex-2-en-1-one 25aS. This 
metabolite was also isolated as a dehydration product 
of (2S,3S,4S)-3,4-dihydroxy-2-
methoxycyclohexanone 17acis (Scheme 4).  
A repeat biotransformation of guaiacol 4a 
again resulted in the formation of chiral metabolites 
17acis, 25aS and 19aS, but in a different ratio based on 
isolated yields, i.e. 11%, 3%, <1% respectively. This 
prompted a time course biotransformation study of 
methoxyphenol substrates 3a and 4a, which showed 
increases in the relative yields of 4-hydroxy-3-
methoxycyclohex-2-en-1-ones 19aS and 25aS 
respectively, with glucose, rather than pyruvate, as a 
carbon source and during the later stages (>8 h) of the 
biotransformations. 
The unexpected discovery of 4-
hydroxymethoxycyclohex-2-en-1-ones 19aS and 25aS, 
metabolites of phenol substrates 3a and 4a, allied to 
the earlier isolation of compound 19eR, as a minor 
metabolite of 3-iodophenol 3d,[5a] raised the possibility 
that compounds 19aS, 25aS and.19eR could be the first 
members of a new family of phenol metabolites. To 
investigate the possible metabolic pathways, leading 
to the formation of 4-hydroxycyclohex-2-en-1-ones 
19aS, 19eR and 25aS, repeat biotransformations of 3-
iodophenol 3d and ortho-cresol 4b were conducted 
(Scheme 4).  
Iodocyclohex-2-en-1-one cis-diol 6d, a major 
metabolite of 3-iodophenol 3d,[5a,c] was isolated in 
variable yields (30-70%), along with other metabolites 
including 4-hydroxycyclohex-2-en-1-one 19eR. LC-
TOFMS analysis of the biotransformed aqueous 
culture medium, detected the presence of 
cyclohexanone cis-diol 26e and GC-MS analysis of the 
EtOAc concentrate, after trimethylsilylation with N-
methyl-N-(trimethylsilyl)trifluoroacetamide 
(MSTFA), showed that iodocyclohexene cis-triol 12d, 
cyclohexane cis-triol 18e, iodocatechol 13d, 
iodohydroquinone 16d and cyclohexene cis-triol 12 
(R=H) were also present as minor metabolites 
(Scheme 2, 4 and Fig 2).  
A preliminary biotransformation of ortho-
cresol 4b, resulted in the isolation of (4S,5R,6S)-4,5-
dihydroxy-6-methylcyclohex-2-en-1-one 8b, as the 
only identified metabolite (1% yield).[5a] Repeated 
metabolism studies of phenol 4b, revealed that in 
addition to cis-diol 8b, four other minor metabolites 
were present. Catechol 13b and hydroquinone 16b 
were identified by trimethylsilylation of a small 
portion of the crude freeze-dried extract, followed by 
GC-MS analysis of the products and comparison with 
authentic samples.  
Time course LC-TOFMS analysis, of the 
crude culture medium from a biotransformation of 
ortho-cresol 4b, indicated that, in addition to 8b, a 
very minor bioproduct was formed, which rapidly 
metabolized further. This early eluting bioproduct, 
was tentatively identified as cyclohexanone cis-diol 
17bcis (Scheme 4). Its identity was confirmed by 
catalytic hydrogenation (Pd/C, MeOH) of metabolite 
8b, to yield an identical sample of (2S,3R,4S)-3,4-
dihydroxy-2-methylcyclohexanone 17bcis. Work up of 
the biotransformed material[5a] and separation of the 
crude mixture, by column chromatography followed 
by PLC of early eluting fractions, gave a new 
metabolite, which was identified as 4-hydroxy-2-
methylcyclohex-2-en-1-one 25bS ([α]D - 49.0). The 
opposite enantiomer, 25bR, ([α]D + 46.7), had been 
synthesised earlier by an alternative route, involving 
manganese acetate-mediated acetoxylation and lipase-
catalysed ester hydrolysis.[7] 
(iii) Biosynthetic pathways for the formation of 4-
hydroxycyclohex-2-en-1-one - metabolites from 
phenols  
The metabolic sequences, to account for the formation 
of the 4-hydroxycyclohex-2-en-1-one metabolites 
19eR, 19aS, 25aS and 25bS, as minor products from the 
corresponding phenol substrates (3d, 3a, 4a and 4b), 
via the initial cyclohexenone cis-diol metabolites 6d, 
6e, 6a, 8a and 8b, are presented in Scheme 4.  
It is proposed that, during the P. putida UV4 
biotransformation of 3-iodophenol 3d, an ERED-
catalysed ene reduction of cyclohexenone cis-diol 6d, 
followed by a dehydrohalogenation of the resulting 
cyclohexanone cis-diol could occur, to give the 
transient parent cyclohex-2-en-1-one cis-diol 6e 
(Scheme 4). Intermediate 6e was not detected, possibly 
due to its further rapid ERED-catalysed ene reduction 
to form the detected transient metabolite 26e. CRED-
catalysed reduction of metabolite 26e yielded the cis-
triol metabolite 18e (Fig. 2, R = H), while its facile 
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dehydration also gave 4-cyclohex-2-ene-1-one 19eR. 
A precedent for this type of reductive dehalogenation 
mechanism, (6d 6e) by the ERED-catalysed 
reduction-spontaneous β-elimination of β-halo-α,β-
unsaturated carboxylic esters, has been reported.[8] 
Other examples of ERED-catalysed ene reductions, of 
α,β-unsaturated ketones, e.g. metabolites 8a→17acis 
and 8b→17bcis, have been found during 
biotransformations[5e] (Scheme 4).  
Further evidence of the metabolic sequence 
(3d 6d 6e 26e 19eR), involving both 
TDO and ERED enzymes, was found when cyclohex-
2-en-1-one cis-diol 6e ([α]D - 217), obtained by 
hydrogenolysis of metabolite 6d, was added as 
substrate. 4-Hydroxycyclohex-2-en-1-one 19eR and 
triol 18e were the only identified metabolites. 
Enantiopure 4-hydroxycyclohex-2-en-1-one 19eR, 
([α]D +110) synthesised by an alternative 
chemoenzymatic route using lipase enzymes, has been 
utilized as a chiral precursor in synthesis.[9a,b] 
Biosynthetic sequences, involving TDO-
catalysed cis-dihydroxylation of phenols 4a and 4b, to 
yield enantiopure cyclohex-2-en-1-one cis-diols 
followed by an ERED-catalysed reduction / β-
elimination mechanism, are shown in Scheme 4. The 
metabolic pathway proposed for the formation of 4-
hydroxycyclohex-2-en-1-one 25aS from phenol 4a, 
(4a 8a 17acis 25aS), was supported by results 
obtained using (2S,3S,4S)-cyclohexanone cis-diol 17a 
as substrate; compound 25aS was the only bioproduct 
formed. It was presumed that the biotransformation of 
phenol 4b, to yield 4-hydroxycyclohex-2-en-1-one 
25bS, would also occur via a similar metabolic 
pathway (4b 8b 17bcis 25bS).  
While the formation of three 4-
hydroxycyclohex-2-en-1-ones (19eR, 25aS and 25bS), 
from the corresponding phenol substrates (3d, 4a and 
4b), resulted from a common biosynthetic sequence, 
this pathway would not result in the formation of 
metabolite 19aS from phenol 3a. Furthermore, the 
higher enantiopurity (>98% ee), of bioproducts 19eR, 
25aS and 25bS from phenols 3d, 4a and 4b, contrasted 
with the lower ee value of metabolite 19aS (ca. 65% 
ee, from phenol 3a) found earlier. This indicates the 
probability of a different mechanism being involved in 
the formation of 4-hydroxycyclohex-2-en-1-one 19aS 
from phenols 3a and 4a.  
With cyclohexenone cis-diol 6a as substrate, 
4-hydroxycyclohexenone 19aS was identified as the 
main metabolite with hydroquinone 16a as a minor 
product resulting from the dehydration. Since 
hydroquinone 16a also being formed by the 
dehydration of cyclohexenone cis-diol 8a, its possible 
role as an intermediate during formation of 4-
hydroxycyclohex-2-en-1-one 19aS was examined. The 
biotransformation pathways of phenols 3a and 4a, 
with hydroquinone 16a as an intermediate, were 
postulated to proceed in five steps (3a 6a 16a
27a 28a 19aS and 4a 8a 16a 27a
28a 19aS) as shown in Scheme 4. Further 
confirmation of these metabolic sequences was 
obtained by the biotransformation of hydroquinone 
16a as substrate to yield metabolite 4-
hydroxycyclohex-2-en-1-one 19aS.  
It is postulated that the oxidation of 
hydroquinone 16a, to benzoquinone intermediate 27a, 
could have resulted from either a non-enzymatic 
autoxidation or peroxidase activity in P. putida UV4 
cells, followed by an ERED-catalysed reduction of 
benzoquinone 27a (Scheme 4). The transient 
intermediate, cyclohex-2-ene-1,4-dione 28a, could 
either tautomerize back to hydroquinone 16a or 
undergo an asymmetric CRED-catalysed ketone 
reduction. It could account for metabolite 19aS having 
a lower enantiopurity (65% ee) compared with cis-diol 
precursors 6a and 8a (>98% ee).  
Fungal metabolism of benzoquinone 29, with 
cultures of Phanerochaete chryosporium,[10] to form 4-
hydroxycyclohex-2-enone 30 (Fig.3) provides a 
precedent for the metabolic sequence (27a 28a
19aS)  Dehydration of cyclohexenone cis-diols 6a and 
8a, to give hydroquinone 16a, and of cyclohexanone 
cis-diols 17a, 17b and 26e, to form 4 -
hydroxycyclohex-2-en-1-ones 25aS, 25bS and 19eR 
respectively, could occur during biotransformations, 
via chemocatalysis or a dehydratase-catalysed process.  
(iv) Biotransformations of monocylic arenes, to 
yield arene hydrates 
The hydration of conjugated and non-conjugated 
alkene bonds, catalysed by hydratase or hydrolyase 
enzymes, e.g. aconitase, fumarase and crotonase, is a 
common step in primary metabolism.[11a] There are 
very few reported examples of enzymatic hydrations 
of arenes, to form the corresponding arene hydrates. 
The formation of arene hydrate metabolite 31 from 
acetophenone substrate 1 (R = COMe) using P. putida 
UV4 cultures, is among the few reports of arene to 
arene hydrate biotransformations (Scheme 1, Fig. 
3).[11b]   
Metabolite 31, a highly unstable compound, 
with a propensity to rapidly dehydrate back to 
substrate 1 (R = COMe), was only identified as an iron 
tricarbonyl complex.[11b] To study the stability of 
monocyclic arene hydrates, racemic samples of 
compounds 32 (R = Me, Et, iPr, tBu), and 33 (R = 
CO2Me and Ph), were synthesised from 3-substituted  
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Scheme 4. Metabolic pathways for the formation of 4-hydroxycyclohex-2-en-1-ones 19eR, 19aS, 25aS and 25bS, 
from phenols 3d, 3a, 4a and 4b respectively.
 
 
Figure 3. Structures of compounds 29-36. 
1,4-cyclohexadienes,[11c] and enantiopure arene 
hydrates 33 (R = F, Cl, Br. CF3) and 34 (R = Br) from 
the corresponding cis-dihydrodiol metabolites 2.[11d] 
Kinetic studies of the acid-catalysed dehydration of 
these arene hydrates showed that they aromatized 
much faster (3.7x102 - 6.9x 104 fold) than cis-
dihydrodiols 2.[11c]  
The monocyclic arene hydrate 35, an unstable 
intermediate, formed during the biosynthesis of the 
antibiotic bacilysin, was obtained by the enzymatic 
decarboxylation of prephenate, using an E. coli 
recombinant strain, expressing phenate 
decarboxylase.[12a-c] Arene hydrate 35 was found to 
undergo a slow non-enzymatic, or a rapid enzyme-
catalysed isomerization, to yield the more stable 
vinylogous 4-hydroxycyclohexenone metabolite 36. 
Intermediate 35 appears to be among the very few, 
isolated and fully characterized, monocyclic arene 
hydrate metabolites. 
Phenol metabolites, 4-hydroxycyclohex-2-en-
1-one 19eR, 19aS, 25aS and 25bS, identified during the 
study could, in principle, equilibrate with the 
corresponding phenol hydrate tautomers 19e'R, 19a'S, 
25a'S and 25b'S; in practice only the keto tautomers 
were observed by NMR spectroscopy. Similarly, the 
methoxycyclohexenone cis-diol 6a, metabolite of 3-
methoxyphenol 3a, showed no evidence of enol 
tautomer 5a, from proton NMR analysis (Scheme 1). 
Trimethylsilylation of cis-diol 6a with MSTFA, and 
GC-MS analysis of the product, showed a major peak 
(95%) with ([M]+ m/z 302), indicating formation of the 
diTMS derivative.[5e] The molecular ion ([M]+ m/z 
374), corresponding to the minor peak (5%), was from 
a triTMS derivative and provided indirect evidence of 
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the elusive enol tautomer 5a. Similar treatment of 4-
hydroxycyclohex-2-en-1-ones 19eR and 19aS with 
MSTFA, and GC-MS analyses of the products showed 
the formation of monoTMS derivatives 19e'R and 
19a'S (major peaks). The minor peaks were attributed 
to the diTMS derivatives of the undetected phenol 
hydrate tautomers 19e'R and 19a'S. 
The lack of evidence, for monocyclic arene 
hydrates of similar structure to metabolite 31,[11b] 
during the biotransformations of substituted benzene 
substrates by P. putida UV4 or other microbial 
systems  could be due to the absence of suitable 
hydrolase / hydratase enzymes or rapid dehydration 
and reformation of the arene substrates.[11c] Under 
similar biotransformation conditions, the TDO-
catalysed cis-dihydroxylation of arene hydrate 33 (R = 
CF3) yielded the opposite enantiomer of cyclohexene 
triol 12c,[11d] and thus revealed an alternative 
metabolic pathway for monocyclic arene hydrates. The 
results presented herein demonstrate that the more 
stable keto tautomers of arene hydrates can be 
obtained from phenols using P. putida UV4.  
Conclusion 
Molecular docking results, of four aniline substrates 
with TDO, led to the prediction that in common with 
phenols, cis-dihydroxylation of anilines could occur, 
to yield cis-diols and catechols. The premise was 
confirmed by the detection and isolation, of identical 
cyclohex-2-en-1-one cis-diol metabolites, from the 
corresponding meta-phenols and meta-anilines. The 
initial formation of enamines and the NH-imine 
tautomers, followed by their rapid hydrolysis, could 
account for the formation of cyclohex-2-en-1-one cis-
diols in low yields from the anilines. Although 
catechols had been found earlier as aniline 
metabolites, no direct evidence was found in the study, 
possibly due to further metabolism by catechol 
dioxygenase. 
Biotransformation of cyclohex-2-en-1-one 
cis-diols, resulted in the formation of a new range of 
minor metabolites, which were identified as 4-
hydroxycyclohex-2-en-1-ones. Their structures and 
absolute configurations were determined by 
chemoenzymatic synthesis and stereochemical 
correlation and have considerable synthetic potential. 
Although single step hydratase or hydrolase 
activity has been reported for alkenes, we are unaware 
of similar activity with arene substrates. Multistep 
metabolic pathways, involving cyclohexenone cis-
diol, cyclohexanone cis-diol and hydroquinone 
intermediates, are now proposed to explain the 
formation of 4-hydroxycyclohex-2-en-1-ones as a new 
type of phenol metabolite. Although direct evidence 
for the presence of enol tautomers (arene hydrates) of 
4-hydroxycyclohexenones was not found, indirect 
evidence was obtained following trimethylsilylation 
and GC-MS analyses. 
 
Experimental Section 
Experimental Details 
NMR spectra were recorded on Bruker Avance-400, DPX-
300 and DRX-500 instruments. Chemical shifts (δ) are 
reported in ppm relative to SiMe4, and coupling constants 
(J) are given in Hz. IR spectra were recorded on a Perkin-
Elmer 983G spectrometer. Optical rotation ([α]D) 
measurements were carried out on a Perkin-Elmer 214 
polarimeter. LC-TOFMS analyses were conducted using an 
Agilent 1100 series HPLC coupled to an Agilent 6510 Q-
TOF (Agilent Technologies, USA) and a reverse phase 
column (Agilent Eclipse Plus C18, 5 mm, 150 x 2.1 mm) 
under reported conditions.[5e] GC-MS analysis of 
metabolites was carried after silylation using MSTFA and 
an Agilent Technologies 6890N gas chromatograph linked 
to a 5973 mass selective detector and Agilent Technologies 
HP Ultra 2 column as reported.[5e]  For TLC analysis, Merck 
Kieselgel 60F254 analytical plates were used and PLC 
separation of metabolites was carried out using glass plates 
(20 cm x 20 cm) coated with Merck Keiselgel PF254/366 silica 
gel. Column chromatography was performed on Merck 
Keiselgel type 60 (250-400 mesh). 
Phenols 3a-3d, 4a, 4b, anilines 9a-d, catechols 13a, 13b, 
hydroquinones 15a, 15b and methoxybenzoquinone 27a 
were purchased from Sigma-Aldrich Co. Authentic samples 
of cyclohex-2-en-1-one cis-diols 6a-d and cyclohexene cis-
triol 12c were available from earlier studies.[5a-e] 
Commercially obtained anilines 9a-d showed no detectable 
traces of phenols 4a-d on GC-MS analysis, prior to their use 
as substrates. Biotransformations were carried out using P. 
putida UV4 cells, unless mentioned otherwise. 
Molecular modelling  
Substrate docking studies were performed according to an 
earlier procedure.[5f] The required in silico models of 
substrates were created in .pdb-format with UCSF Chimera 
1.10.2 (https://www.cgl.ucsf.edu/chimera/). In silico 
dockings were performed with AutoDock suite 4.2 
(autodock4, autogrid4). The Graphical User Interface 
(GUI), including python scripts for ligand and receptor 
preparation, was part of AutoDock Tools 1.5.6. AutoDock 
suite and AutoDock tools (ADT) are provided by the 
Scripps Research Institute (http://autodock.scripps.edu/).[13] 
The TDO crystal structure was accessed from the Protein 
Data Bank (PDB code 3en1, resolution of 3.2 Å). The raw 
3en1 crystal structure .pdb-file of TDO includes a docked 
toluene structure in the active site, which was removed with 
UCSF chimera 1.10.2 prior to docking. The resulting model 
was called 3EN1M. Ligand and receptor were then prepared 
in accordance with the ADT tutorial 
 11 
(http://autodock.scripps.edu/faqs-help/tutorial/using-
autodock-4-with autodocktools/2012_ADTtut.pdf) utilising 
the ‘prepare_receptor4.py’ python script included in ADT, 
missing atoms were repaired, hydrogens and Gasteiger 
charges added, and non-polar hydrogens merged. The 
resulting .pdbqt-file of the crystal structure was used in all 
docking calculations. .pdb-files of substrates were 
automatically converted to the required .pdbqt-format by 
ADT. The docking grid was adjusted to include all amino 
acids within 5 Å of toluene in the crystal structure: Gln215, 
Phe216, Asp219, Met220, His222, Ala223, His228, Val309, 
His311, Leu321, Ile324, Phe366, Phe376. 
PyMol was used to incorporate dioxygen into the 3EN1M 
model, by superimposing the iron complex (Fe, His222, 
His228, and Asp376) of TDO (pdb code: 3en1) with that of 
NDO (pdb code: 1o7m), and copying the dioxygen positions 
to 3EN1M. The resulting model was called 3EN1M-O2. 
Docking resolution = 0.247 Å; xsize = 40; xoffset = 12.833; 
ysize = 60; yoffset = -4.472; zsize = 72; zoffset = 3.917. The grid 
parameter file (.gpf) was used to create the grid map files 
(.glg) using autogrid4. The search protocol for docking used 
the internal default docking parameters of AutoDock 4.2, 
starting the ligand at a random location. The docking was 
set to be performed as 100 runs of the Lamarckian genetic 
algorithm with a population size of 150 each, terminating 
after 2 500 000 energy evaluations or 27 000 generations 
(whichever occurs first; standard settings). The docking 
results  were analysed with ADT, to obtain docking 
coordinates, calculated binding energy (in kJ) and 
calculated dissociation constant KD (in µM). All docking 
studies were performed as rigid docking, keeping all 
positions, orientations and protonation states of all amino 
acid atoms locked in place. The 100 docking orientations 
were automatically analysed by ADT and divided into 
orientationally and energetically similar groups. The 
orientation with the highest binding energy of each group 
was saved as representative for each group. The 
conformation of toluene, in the crystal structure, was used 
as a reference, to establish and confirm the viability of the 
docking procedure and parameters, as a similar 
conformation was obtained from docking with ADT. 
3D visualization 
The amino acids of the TDO active site were visualized with 
PyMol 1.7.4.5, from the Protein Data Bank (PDB) 3EN1 file 
coordinates. The docking results were imported into PyMol, 
from the respective .pdb files created with AutoDock4 and 
AutoDock Tools. Measurements between atoms were 
calculated with PyMol’s incorporated measurement tool. 
Biotransformation of anilines 9a-d  
Initial small scale biotransformations of anilines 9a-d and 
LC-TOFMS analyses of metabolites were conducted, under 
conditions similar to those reported for phenol substrates.[5a-
e] However, due to the increased toxicity of anilines 9a-d, 
compared with phenol substrates 3a-d, a significant 
proportion of residual aniline substrates were consistently 
present along with cyclohexenone cis-diol metabolites 6a-
d. To achieve complete conversions, lower aniline 
concentrations were used (ca. 0.05 mg/ml). Cyclohexenone 
cis-diol metabolites 6a-d and cis-triol 12c were readily 
identified as aniline metabolites, by comparison of LC-
TOFMS data with the authentic samples. As cyclohexenone 
cis-diols 6a-d and cis-triol 12c had been fully characterised 
[5a-e], only the LC-TOFMS retention times (min.) and 
accurate mass values were recorded for aniline substrates 
9a-d. 
3-Methoxycyclohex-2-en-1-one cis-diol 6a.[5d] 3.43 min., 
HRMS: [M+H]+ 159.0646, calcd. for C7H11O4 159.0652. 
3-Methylcyclohex-2-en-1-one cis-diol 6b.[5a] 4.85 min., 
HRMS: [M+H]+ 143.0698, calcd. for C7H11O3 143.0703. 
3-Trifluoromethylcyclohex-2-en-1-one cis-diol 6c.[5c] 
10.93 min., HRMS: [M+H]+ 197.0417, calcd. for C7H8O3F3 
197.0420. 
3-Iodocyclohex-2-en-1-one cis-diol 6d.[5a] 10.19 min., 
HRMS: [M+H]+ 254.9502, calcd. for C6H8O3I 254.9513. 
  
6-Trifluoromethylcyclohex-5-ene cis-triol 12c.[5c] 9.65 
min., HRMS: [M+NH4]+ 216.0831, calcd. for C7H13NO3F3 
216.0847. 
Cyclohex-2-en-1-one cis-diol metabolite 6a (ca. 6 mg) was 
isolated from a biotransformation of aniline 9a (1.25 g in 4 
L culture medium). Purification, by column chromatograph 
(hexane → EtOAc), of the crude product obtained after 
usual work up followed by PLC (50% EtOAc in hexane), of 
selected combined fractions, gave metabolite 6a. The 
metabolite was found to have identical spectroscopic 
(NMR) and chiroptical ([α]D) properties to an authentic 
sample derived from phenol 3a. No catechol metabolites [6a-
e] were detected (GC-MS analysis) in the crude bio-extracts 
of aniline substrates 9a-d.  
Biotransformation of phenols 3a, 3d, 4a and 4b and 
synthesis of (-)-(S)-4-hydroxy-3-methoxycyclohex-2-en-
1-one 19aS  
Large scale biotransformations of phenols 3a and 4a, using 
whole cell cultures of P. putida UV4 with glucose as a 
carbon source, were reported.[5e] Pooled column fractions, 
from that investigation containing unidentified metabolites, 
were re-examined during the current study. Time course 
study of small scale biotransformations of phenols 3a, 3d, 
4a and 4b and anilines 9a-d, were conducted under similar 
conditions, using glucose or pyruvate as carbon sources.[5a-
e] Chiral metabolites, 4-hydroxycyclohex-2-en-1-ones 19a, 
19e, 25a and 25b, cyclohexenone cis-diols 6a and 6d, 
cyclohexanone cis-diols 17a, 17b and 26e, and cis-triol 12c 
were detected directly in the crude aqueous culture medium 
by LC-TOFMS analyses, prior to their isolation. Catechols 
13a-d, hydroquinones 16a-d were identified by GC-MS 
analyses of the crude bio-extracts, after EtOAc extraction 
and trimethylsilylation (MSTFA) of the dried concentrates.  
(a) 4-Hydroxy-3-methoxycyclohex-2-en-1-one 19aSa new 
metabolite of 3-methoxyphenol 3a 
In the large scale biotransformation  of phenol 3a, the major 
metabolite, cyclohex-2-en-1-one cis-diol 6a (45 g, 38% 
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yield), was isolated by crystallization from the crude 
extract.[5e] GC-MS analysis of the retained combined 
fractions showed that catechol 13a and hydroquinone 14a 
were also present among a mixture of unidentified 
metabolites. One very minor metabolite was identified as 2-
hydroxy-6-methoxy-6-oxohexanoic acid 15a by LC-
TOFMS analysis: [M+H]+ 177.0758, calcd. for C7H13O5 
177.0758; [M+Na]+ 199.0577, calcd. for C7H12O5Na 
199.0582; [M+NH4]+ 194.1018, calcd. for C7H16NO5 
194.1028. LC-TOFMS analysis of the combined fractions 
indicated that another unidentified metabolite was present; 
its molecular weight was consistent with structure 19aS. 
Separation of the combined fractions by careful column 
chromatography (hexane →50% EtOAc in hexane) gave a 
pure sample of metabolite 19aS. 
(4S)-4-Hydroxy-3-methoxycyclohex-2-en-1-one 19aS,[14] 
Colourless oil (1.2 g, 1%); Rf  0.15 (50% EtOAc in hexane); 
[α]D - 31.9 (c 1.0, CHCl3); HRMS: (TOF-LCMS) [M+H]+ 
143.0709, calcd. for C7H11O3  143.0708; 1H NMR (400 
MHz) δ = 2.01 (1 H, ddddd, J =12.5, 10.1, 7.9, 4.3, 0.6 Hz, 
H-5), 2.25-2.37 (2 H, m, H-5', H-6), 2.59 (1 H, m, H-6'), 
2.65 (1 H, br s, OH), 3.76 (3 H, s, Me), 4.47 (1 H, dd, J =8.4, 
5.0 Hz, H-4), 5.34 (1 H, s, H-2), 13C NMR (100 MHz) δ = 
29.5, 34.0, 56.2, 65.8, 102.1, 176.2, 198.6; IR (film) 
νmax/cm-1 3389, 2945, 1630, 1609, 1231. 
(b) Chemoenzymatic synthesis of (S)-4-hydroxy-3-
methoxycyclohex-2-en-1-one 19aS 
(S)-2-Bromo-2-cyclohexen-1-ol 21S. This compound was 
available as a colourless oil from an earlier 
biotransformation [5h] of 2-bromo-2-cyclohex-2-en-1-one 
20, [α]D - 80.3 (c 1.77, CHCl3), ee  99.8% (chiral GC 
analysis). 
(S)-(2-Bromocyclohex-2-enyloxy)-tert-
butyldimethylsilane 22S.[15] tert-Butyldimethylsilyl 
trifluoromethanesulfonate (280 μl, 1.21 mmol) was added to 
a solution of alcohol 21S (200 mg, 1.10 mmol), maintained 
at 0°C in dry CH2Cl2 (10 mL) containing triethylamine (240 
μl, 1.69 mmol). The reaction mixture was stirred (2 h) at 
0°C, allowed to warm to room temperature and then ice (20 
g) and CH2Cl2 (20 mL) were added to it. After thoroughly 
mixing the reaction mixture by shaking, the organic layer 
was separated, washed with brine (15 mL), dried (Na2SO4), 
and concentrated to give a yellow oil. It was purified by 
flash chromatography (hexane) to yield the TBS ether 22S 
as a colourless oil (310 mg, 94%); Rf 0.4 (hexane); [α]D - 
82.9 (c 0.8, CHCl3); 1H NMR (400 MHz) δ = 0.11 (3 H, s, 
SiMe), 0.17 (3 H, s, SiMe), 0.92 (9 H, s, CMe3), 1.40 (1 H, 
m, H-5), 1.55-1.68 (3 H, m, H-5', H-6, H-6'), 1.83 (1 H, m, 
H-4), 1.95 (1 H, m, H-4'), 4.02 (1 H, m, H-1), 5.97 (1 H, dd, 
J = 4.7, 3.7 Hz, H-3); 13C NMR (100 MHz,) δ = - 4.5, - 4.3, 
17.4, 18.3, 26.0 (3C), 27.9, 33.9, 70.8, 126.0, 132.1; IR 
(film): νmax/cm-1 2949, 2930, 1644, 1252, 1093.  
(S)-3-Bromo-4-(tert-butyldimethylsilyloxy)cyclohex-2-
en-1-one 23S. A solution of tert-butyl hydroperoxide in 
water (6 M, 0.63 mL, 3.78 mmol) was added dropwise into 
a mixture of TBS ether 22S (200 mg, 0.68 mmol), K2CO3 
(47 mg, 0.34 mmol), diacetoxyiodobenzene (670 mg, 2.1 
mmol) and butyl butyrate (1.5 mL) maintained at 0°C. The 
reaction mixture was stirred (0°C, 8 h), diluted with a 
mixture of 20% ether in hexane (10 mL), filtered 
(diatomaceous earth), and the filtrate concentrated to give a 
crude yellow oil. It was purified by column chromatography 
(5% Et2O in hexane) to give enone 23S as a colourless oil 
(60 mg, 29%); Rf  0.28 (5% Et2O in hexane); [α]D + 41.5, (c 
0.5, CHCl3); HRMS: (LC-TOFMS) [M+H]+ 305.0560, 
calcd. for C12H22O2SiBr 305.05670; 1H NMR (400 MHz) δ 
= 0.15 (3 H, s, SiMe), 0.20 (3 H, s, SiMe), 0.93 (9 H, s, 
CMe3), 2.07 (1 H, dddd, J = 13.7, 7.8, 6.0, 4.6 Hz, H-5), 
2.25 (1 H, dddd, J = 13.7, 9.1, 4.6, 4.0, H-5' Hz), 2.38 (1 H, 
ddd, J = 16.9, 7.8, 4.6 Hz, H-6), 2.67 (1 H, ddd, J = 16.9, 
9.2, 4.6 Hz, H-6'), 4.50 (1 H, dd, J = 6.0, 4.0 Hz, H-4), 6.44 
(1 H, s, H-2); 13C NMR (100 MHz) δ = - 4.6, - 4.4, 18.3, 
25.8 (3C), 32.0, 33.4, 71.0, 132.8, 152.6, 196.0; IR (film) 
νmax/cm-1 2954, 1689, 1610, 1471. 
(S)-4-(tert-Butyldimethylsilyloxy)-3-methoxycyclohex-2-
en-1-one 24S. To a solution of enone 23S (40 mg, 0.13 
mmol) in MeOH (2 mL) was added K2CO3 (35 mg, 0.26 
mmol), and the mixture kept at room temperature (2 h) 
without stirring. The reaction mixture was filtered, the 
filtrate carefully concentrated in vacuo, and the light yellow 
volatile oil obtained was purified by PLC (10% Et2O in 
pentane) to  furnish methoxy compound 24S as a colourless 
oil (23 mg, 69%); Rf  0.2 (5% Et2O in pentane); HRMS: (ES) 
[M+H]+ 257.1571, calcd. for C13H25O3Si 257.1573; 1H 
NMR (400 MHz) δ = 0.08 (3 H, s, SiMe), 0.11 (3 H, s, 
SiMe), 0.89 (9 H, s, CMe3), 1.95-2.14 (2 H, m, H-5, H-5'), 
2.29 (1 H, ddd, J = 16.7, 5.8, 4.4 Hz, H-6), 2.67 (1 H, ddd, 
J = 16.7, 10.1, 5.0 Hz, H-6'), 3.70 (3 H, s, OMe), 4.32 (1 H, 
dd, J = 5.0, 4.1 Hz, H-4), 5.27 (1 H, s, H-2); 13C NMR (100 
MHz) δ = - 5.0, - 4.6, 18.3, 25.8 (3C), 31.0, 32.9, 55.8, 67.2, 
102.2, 176.9, 199.3; LRMS: (EI): 217 (100), 257 (5), 304 
(60), 445 (50), 1065 (15); IR (film) νmax /cm-1 2955, 2930, 
1670, 1618, 1226, 834. 
(S)-4-Hydroxy-3-methoxycyclohex-2-en-1-one 19aS. A 
THF solution  of tetrabutylammonium fluoride (1 M, 118 
µl, 0.12 mmol) was added to a solution of compound 24S 
(20 mg, 0.08 mmol) in THF (4 mL) at 0°C. The reaction 
mixture was stirred and allowed to warm slowly (2 h) to 
10°C. The concentrated reaction mixture was purified by 
PLC (50 % EtOAc in hexane) to give hydroxyenone 19aS as 
a colourless oil (7 mg, 62%); Rf 0.15 (50% EtOAc in 
hexane); [α]D - 48.8 (c 0.53, CHCl3). The synthetic sample 
of hydroxyenone 19aS was found to be identical with the 
enzymatically formed metabolite 19aS. 
(c) New metabolites of 2-methoxyphenol 4a  
LC-TOFMS analysis of the aqueous bio-extract, obtained 
from the biotransformation of 2-methoxyphenol substrate 
4a, showed the presence following metabolites: 
cyclohexanone cis-diols 17acis and 17atrans, cyclohex-2-en-
1-one cis diol 8a, hydroquinone 16a, catechol 13a and its 
hydroxycarboxylic acid derivative 15a, and some 
unidentified bioproducts.[5e] The large-scale 
biotransformation of 2-methoxyphenol 4a and purification 
by column chromatography (hexane → EtOAc) had yielded 
(2S, 3S, 4S)-cis-diol 17acis (2.5 g) and (2R, 3S, 4S)-trans-
diol 17atrans (0.25 g).[5e] LC-TOFMS analysis of unidentified 
pooled chromatography fractions (2.6 g, eluent 50% EtOAc 
 13 
in hexane), indicated it to be a mixture (9:1) of two isomeric 
compounds ([M+H]+ 143), which could not be separated. 
This retained concentrated mixture was  re-examined during 
the study. A pure sample of the major isomer, separated by 
multiple elution PLC (2.5% MeOH in CHCl3), was 
identified as 4-hydroxy-2-methoxycyclohex-2-en-1-one 
25aS. The minor isomer of the mixture was found to be 
indistinguishable from metabolite 4-hydroxy-3-
methoxycyclohex-2-en-1-one 19aS, which was derived 
from 3-methoxyphenol 3a. 
(4S)-4-Hydroxy-2-methoxycyclohex-2-en-1-one 25aS. 
Light yellow oil, Rf  0.26 (5% MeOH in CHCl3); [α]D - 29.0 
(c 1.1, CHCl3); HRMS: (LC-TOFMS) [M+H]+ 143.0703, 
calcd. for C7H11O3 143.0708; [M+Na]+ 165.05216, calcd. 
for C7H10O3Na 165.0528; [M+K]+ 181.0261, calcd. for 
C7H10O3K 181.0267; [M+H - H2O]+ 125.0523, calcd. for 
C7H8O2 125.0524; 1H NMR (400 MHz) δ = 1.94 (1 H, dddd, 
J = 12.6, 11.0, 8.1, 4.5 Hz, H-5), 2.28 (1 H, m, H-5'), 2.40 
(1 H, ddd, J = 17.0, 11.1, 4.6 Hz, H-6), 2.56 (1 H, bs, OH), 
2.68 (1 H, ddd, J = 17.0, 6.3, 4.5 Hz, H-6'), 3.60 (3 H, s, 
OMe), 4.68 (1 H, m, H-4), 5.82 (1 H, dd, J = 3.5 Hz, 0.6, H-
3); 13C NMR (100 MHz) δ = 32.6, 35.2, 55.5, 66.5, 118.8, 
151.4, 194.0. Addition of (2S, 3S, 4S)-3,4-dihydroxy-2-
methoxycyclohexanone 17acis as substrate to P. putida UV4, 
resulted in the formation of metabolite 4-hydroxy-2-
methoxycyclohex-2-enone 25aS  and provided confirmation 
of its (4S) absolute configuration by stereochemical 
correlation.  
(d) New metabolites of 2-methylphenol (o-cresol) 4b 
Biotransformation (P.putida UV4) of o-cresol 4b was found 
to yield (4S,5R,6S)-4,5-dihydroxy-6-methylcyclohex-2-en-
1-one 8b as the only identified metabolite.[5a] Repeat  
biotransformation of phenol 4b, under similar conditions, 
and GC-MS analysis of a small portion of the crude 
concentrate, after extraction with EtOAc and silylation, 
showed that catechol 13b and hydroquinone 16b were 
present among the minor metabolites. LC-TOFMS analysis 
(4.31 min.) and comparison with an authentic sample, 
confirmed that metabolite 8b was the main component: 
[M+H]+ 143.0702, calcd. for C7H11O3 143.0708 and 
[M+Na]+ 165.0516, calcd. for C7H10O3Na 165.0528. LC-
TOFMS analysis also indicated the presence of 4-hydroxy-
3-methylcyclohex-2-en-1-one 25bS (11.98 min) and 
cyclohexanone cis-diol 17bcis (3.9 min.) as minor 
metabolites. PLC purification (50% EtOAc in hexane) 
yielded 4-hydroxy-3-methylcyclohex-2-en-1-one 25bS; the 
structure and absolute configuration were established by 
comparison with the literature data of its opposite 
enantiomer.  
(4S)-Hydroxy-2-methylcyclohex-2-en-1-one 25bS. Light 
yellow oil (23 mg, 0.56 % yield); Rf 0.20 (50% EtOAc in 
hexane); [α]D - 49.0 (c 0.7, CHCl3), (Lit.[7] Ent. [α]D + 46.7, 
CHCl3); HRMS: (EI) M+ 126.0685, calcd. for C7H10O2 
126.0681; 1H NMR (400 MHz) δ = 1.79 (3 H, s, Me), 1.95 
(1 H, m, H-5), 2.37 (2 H, m, H-4, H-5), 2.62 (1 H, m, H-6), 
2.8 (1 H, br s, OH), 4.55 (1 H, m, H-4), 6.73 (1 H, m, H-3); 
13C NMR (100 MHz) δ = 15.9, 33.1, 35.9, 66.9, 135.9, 
148.4, 199.9. 
(2S,3R,4S)-3,4-Dihydroxy-2-methylcyclohexanone 
17bcis. A solution of 2-methylcyclohex-2-en-1-one cis-diol 
8b (5 mg), in methanol (1 mL) containing 10% Pd/C (ca. 1 
mg), was stirred overnight at room temperature, under 
hydrogen atmosphere and normal pressure. The catalyst was 
filtered off, the filtrate concentrated and the product purified 
by PLC (80% EtOAc in hexane), to give the hydrogenated 
cyclohexanone cis-diol 17bcis. (4.2 mg) as a colourless oil; 
Rf 0.32 (75% EtOAc in hexane); [α]D + 1.2 (c 0.35, MeOH); 
LC-TOFMS: 3.9 min. [M+H]+ 145.0859, calcd. for C7H13O3 
145.0865; [M+NH4]+ 162.1125, calcd. for C7H16NO3 
162.1130; [M+Na]+ 167.0679, calcd. for C7H12O3Na 
167.0684; 1H NMR (400 MHz) δ = 1.14 (1 H, d, J = 6.9 Hz, 
Me), 1.63 (2 H, br s, 2x OH), 2.03-2.20 (2 H, m, H-5, H-5'), 
2.33-2.41 (2 H, m, H-6, H-6'), 2.57 (1 H, qd, J = 6.9, 2.6 Hz, 
H-2), 4.14 (1 H, m, H-4), 4.17 (1 H, ddd, J = 11.0, 5.3, 2.6 
Hz, H-3); 13C NMR (100 MHz) δ = 10.8, 28.4, 38.0, 47.0, 
70.8, 76.9, 209.8. The sample of compound 17bcis obtained 
by hydrogenation showed identical LC-TOFMS data to that 
of metabolite 17bcis. 
(e) GC-MS analysis of diTMS derivatives of 4-
hydroxycyclohex-2-en-1-ones 19eR and 19aS and triTMS 
derivatives of phenol hydrates (cyclohexa-1,5-diene-1,4-
diols) 19e'R and 19a'S 
Trimethylsilylation of metabolites 19eR and 19aS with 
MSTFA, and GC-MS analyses of the silyl derivatives, 
showed two peaks in each case. The major peaks were due 
to the monoTMS derivatives of the keto tautomers 19eR 
(5.05 min., 88%, [M+H]+, m/z = 184) and 19aS (8.61 min., 
81%, [M+H]+, m/z = 214). The minor peaks (6.40 min., 
12%, [M+H]+, m/z = 256) and (8.69 min., 19%, [M+H]+, m/z 
= 286) were consistent with triTMS derivatives of the 
corresponding enol tautomers 19e'R and 19a'S. 
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